Motif Bio PLC has been dealt a serious blow from the US Food and Drug Administration which has told the cash-strapped UK biotech it needs to carry out an additional trial for iclaprim if it wants any hope of getting approval for the antibiotic.
Motif Plunges As FDA Demands New Iclaprim Study
The UK biotech is in dire need of further funding after US regulators requested an additional clinical trial for its much-delayed skin infection antibiotic.
